Defendant Name: Sanofi 

Defendant Type: Public Company
SIC Code: 2834
CUSIP: 80105N10

Document Reference: 34-84017

Document Details

Legal Case Name In the Matter of Sanofi
Document Name Order Instituting Cease-and-Desist Proceedings, Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing Remedial Sanctions and a Cease-and-Desist Order
Document Date 04-Sep-2018
Document Format Administrative Proceeding
File Number 3-18708
AAER 3964
Allegation Type Foreign Corrupt Practices Act
Document Summary On September 4, 2018, the SEC issued an order against Sanofi, stating: "These proceedings arise out of Sanofi's violations of the internal accounting controls and recordkeeping provisions of the Foreign Corrupt Practices Act of 1977 (the "FCPA") [15 U.S.C. § 78m]."

Disgorgement & Penalty Information

Resolutions
Cease and Desist Order
Other Compliance Related Undertaking
Cooperation Before the Resolution
Remedial Acts or Efforts Before the Resolution
Monetary Penalties:

Disgorgement

Individual:     $17,531,666.00 Shared:    

Civil Penalty

Individual:     $5,000,000.00 Shared:    

Pre-Judgment Interest

Individual:     $2,674,479.00 Shared:    

Related Documents:

2018-174 04-Sep-2018 Press Release--Administrative Proceeding
Sanofi Charged With FCPA Violations
On September 4, 2018, the SEC issued a press release regarding charges against Sanofi, stating: "The Securities and Exchange Commission today announced that Paris-based pharmaceutical company Sanofi has agreed to pay more than $25 million to resolve charges that its Kazakhstan and the Middle East subsidiaries made corrupt payments to win business.